scholarly journals Indonesian Rheumatologist Association (IRA) Recommendations for Diagnosis and Management of Peripheral Spondyloarthritis 2021

2021 ◽  
Vol 13 (1) ◽  
pp. 459-475
Author(s):  
Sumartini Dewi ◽  
Arief Nurudhin ◽  
Ayu Paramaiswari ◽  
R.M. Suryo Anggoro Kusumo Wibowo ◽  
Yulyani Werdiningsih ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Strong Recommendation ◽  
Levels Of Evidence ◽  
Diagnosis And Management ◽  
Literature Searches ◽  
Peripheral Spondyloarthritis ◽  
Level Of Agreement

Objective. Spondyloarthritis recommendations are made to provide guidance in diagnosis, treatment, and monitoring of peripheral spondyloarthritis cases.Method. Literature searches were conducted online. The drafting team determines the levels of evidence (LOE) and grades of recommendation (GOR). After conducting a discussion, each recommendation that has been agreed upon by the drafting team is then classified based on the levels of evidence and grades of recommendation. The final step in the preparation of these recommendations is to determine the level of agreement (LOA) on each recommendation carried out by a team of panelists who have been appointed by IRA.Result. Thirty five recommendations regarding peripheral spondyloarthritis were compiled. There are 6 strong recommendation or GOR A for psoriatic arthritis and 8 recommendations for enteropathic arthritis.Conclusion. These recommendations provide directions for clinicians to diagnose and to manage peripheral spondyloarthritis.

scholarly journals Indonesian Rheumatology Association (IRA) Recommendations for Diagnosis and Management of Axial Spondyloarthritis 2021

2021 ◽  
Vol 13 (1) ◽  
pp. 444-458
Author(s):  
Ayu Paramaiswari ◽  
R.M. Suryo Anggoro Kusumo Wibowo ◽  
Yulyani Werdiningsih ◽  
Arief Nurudhin ◽  
Surya Darma ◽  
...  
Keyword(s):  
New York ◽  
Disease Activity ◽  
Therapeutic Response ◽  
Axial Spondyloarthritis ◽  
Sacroiliac Joints ◽  
Levels Of Evidence ◽  
Literature Searches ◽  
Asas Criteria ◽  
The Us ◽  
Level Of Agreement

Objective. Recommendations for spondyloarthritis are made to provide guidelines in diagnosis establishment, therapy, and monitoring of axial spondyloarthritis cases.Method. Literature searches were conducted online. The drafting team determines the levels of evidence (LOE) and grades of recommendation (GOR). After conducting a discussion, each recommendation that has been agreed upon by the drafting team is then classified based on the levels of evidence and grades of recommendation. The final step in the preparation of these recommendations is to determine the level of agreement (LOA) on each recommendation carried out by a team of panelists who have been appointed by IRA.Results. Twenty recommendations regarding axial spondyloarthritis were established. Strong recommendations or GOR A include: Ax-SpA diagnosis can be made according to the 2010 ASAS criteria, or the 1984 modified New York criteria specifically for the US; conventional radiographic examinations and MRI of the sacroiliac joints and vertebrae may be used as evaluators of disease activity and predictors of therapeutic response, as well as patients who do not respond to NSAIDs (within 4 weeks) can be administered a combination of NSAIDs and anti-TNF, and if it is not possible, a combination of NSAIDs and anti-IL-17A (Secukinumab, Ixekizumab).Conclusion. These recommendations provide a direction for clinicians to diagnose and manage spondyloarthritis.

Pulmonary Manifestations in Rheumatoid Arthritis, Psoriatic Arthritis and Peripheral Spondyloarthritis Prevalence, Diagnostic Approach and Treatment Options

2020 ◽  
Vol 16 ◽  
Author(s):  
Daniel Dejcman ◽  
Valentin Sebastian Schäfer ◽  
Dirk Skowasch ◽  
Carmen Pizarro ◽  
Andreas Krause ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Psoriatic Arthritis ◽  
Lung Disease ◽  
Current Knowledge ◽  
Treatment Options ◽  
Pulmonary Diseases ◽  
Chronic Obstructive ◽  
Pulmonary Manifestations ◽  
Major Cluster ◽  
Peripheral Spondyloarthritis

: Interstitial lung disease (ILD) is the most common form of pulmonary impairment in patients with rheumatoid arthritis (RA). However, patients with RA or other arthritic diseases such as psoriatic arthritis (PsA) or peripheral spondyloarthritis (pSpA) may develop several other pulmonary diseases such as chronic obstructive lung disease (COPD) with a higher risk than patients without arthritis. The article at hand aims at summarizing the current knowledge on the prevalence of pulmonary diseases in the above-mentioned forms of arthritis, the challenges for prevalence studies and detecting pulmonary diseases in patients with arthritis as well as possible treatment options. Dyspnea, cough or other pulmonary symptoms or findings in arthritis patients should prompt gradual diagnostic procedures considering pulmonary manifestations as a major cluster of differential diagnosis. Considering its poor prognosis and morbidity burden, RA-ILD needs to be ruled out. Treatment of manifestations often lacks solid evidencebased guidelines and referrals to specialized centers are often necessary.

The Diagnosis and Management of Psoriatic Arthritis in a Professional Football Player Presenting With a Knee Effusion: A Case Report

2008 ◽  
Vol 18 (4) ◽  
pp. 369-371 ◽  
Author(s):  
Robert H Brophy ◽  
C Ronald MacKenzie ◽  
Seth C Gamradt ◽  
Ronnie P Barnes ◽  
Scott A Rodeo ◽  
...  
Keyword(s):  
Case Report ◽  
Psoriatic Arthritis ◽  
Football Player ◽  
Professional Football ◽  
Diagnosis And Management ◽  
Knee Effusion

scholarly journals Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthritis Following Lyme Disease

2016 ◽  
Vol 69 (1) ◽  
pp. 194-202 ◽  
Author(s):  
Sheila L. Arvikar ◽  
Jameson T. Crowley ◽  
Katherine B. Sulka ◽  
Allen C. Steere
Keyword(s):  
Rheumatoid Arthritis ◽  
Psoriatic Arthritis ◽  
Lyme Disease ◽  
Peripheral Spondyloarthritis

Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design

2009 ◽  
Vol 36 (8) ◽  
pp. 1792-1799 ◽  
Author(s):  
WALTER P. MAKSYMOWYCH ◽  
OLIVER FITZGERALD ◽  
GEORGE A. WELLS ◽  
DAFNA D. GLADMAN ◽  
ROBERT LANDEWÉ ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Longitudinal Study ◽  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Study Design ◽  
Validation Studies ◽  
Working Group ◽  
Statistical Strength ◽  
Levels Of Evidence ◽  
Longitudinal Study Design

Objective.At OMERACT 8 a framework for levels of evidence was proposed for the validation of biomarkers as surrogate outcome measures. We aimed to adapt this scheme in order to apply it in the setting of soluble biomarkers proposed to replace the measurement of damage endpoints in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). We also aimed to generate consensus on minimum standards for the design of longitudinal studies aimed at validating biomarkers.Methods.Before the meeting, the Soluble Biomarker Working Group prepared a preliminary framework and discussed various models for association and prediction related to the statistical strength domain. In addition, 3 Delphi exercises addressing longitudinal study design for RA, PsA, and AS were conducted within the working group and members of the Assessments in SpondyloArthritis International Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). This formed the basis for discussions among OMERACT 9 participants.Results.The proposed framework was accepted by consensus. In the study design domain a requirement for both prospective observational studies and randomized controlled trials (RCT) in different drug classes was noted. A template for determining the level of statistical strength was proposed. The addition of a new domain on biomarker assay performance was considered essential, and participants suggested that for any biomarker this domain should be addressed first, i.e., before starting clinical validation studies. Participants agreed on most elements of a longitudinal study design template. Where consensus was lacking the working group has drafted solutions that constitute a basis for prospective validation studies.Conclusion.The OMERACT 9 Soluble Biomarker Group has successfully formulated a levels of evidence scheme and a study design template that will provide guidance to conduct validation studies in the setting of soluble biomarkers proposed to replace the measurement of damage endpoints in RA, PsA, and AS.

scholarly journals Endoscopic management of gastrointestinal motility disorders – part 2: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

Endoscopy ◽  
2020 ◽  
Vol 52 (07) ◽  
pp. 600-614
Author(s):  
Bas L. A. M. Weusten ◽  
Maximilien Barret ◽  
Albert J. Bredenoord ◽  
Pietro Familiari ◽  
Jean-Michel Gonzalez ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Antireflux Surgery ◽  
Zenker’S Diverticulum ◽  
Strong Recommendation ◽  
Quality Of Evidence ◽  
Endoscopic Decompression ◽  
Evidence Level ◽  
Level Of Agreement ◽  
Quality Evidence

Main RecommendationsESGE suggests flexible endoscopic treatment over open surgical treatment as first-line therapy for patients with a symptomatic Zenker’s diverticulum of any size.Weak recommendation, low quality of evidence, level of agreement 100 %.ESGE recommends that emerging treatments for Zenker’s diverticulum, such as Zenker’s peroral endoscopic myotomy (Z-POEM) and tunneling, be considered as experimental; these treatments should be offered in a research setting only.Strong recommendation, low quality of evidence, level of agreement 100 %.ESGE recommends against the widespread clinical use of transoral incisionless fundoplication (TIF) as an alternative to proton pump inhibitor (PPI) therapy or antireflux surgery in the treatment of gastroesophageal reflux disease (GERD), because of the lack of data on the long-term outcomes, the inferiority of TIF to fundoplication, and its modest efficacy in only highly selected patients. TIF may have a role for patients with mild GERD who are not willing to take PPIs or undergo antireflux surgery.Strong recommendation, moderate quality of evidence, level of agreement 92.8 %.ESGE recommends against the use of the Medigus ultrasonic surgical endostapler (MUSE) in clinical practice because of insufficient data showing its effectiveness and safety in patients with GERD. MUSE should be used in clinical trials only.Strong recommendation, low quality evidence, level of agreement 100 %.ESGE recommends against the use of antireflux mucosectomy (ARMS) in routine clinical practice in the treatment of GERD because of the lack of data and its potential complications.Strong recommendation, low quality evidence, level of agreement 100 %.ESGE recommends endoscopic cecostomy only after conservative management with medical therapies or retrograde lavage has failed.Strong recommendation, low quality evidence, level of agreement 93.3 %.ESGE recommends fixing the cecum to the abdominal wall at three points (using T-anchors, a double-needle suturing device, or laparoscopic fixation) to prevent leaks and infectious adverse events, whatever percutaneous endoscopic cecostomy method is used.Strong recommendation, very low quality evidence, level of agreement 86.7 %.ESGE recommends considering endoscopic decompression of the colon in patients with Ogilvie’s syndrome that is not improving with conservative treatment.Strong recommendation, low quality evidence, level of agreement 93.8 %.ESGE recommends prompt endoscopic decompression if the cecal diameter is > 12 cm and if the Ogilvie’s syndrome exists for a duration of longer than 4 – 6 days.Strong recommendation, low quality evidence, level of agreement 87.5 %.

Diagnosis and Management of Psoriatic Arthritis

2014 ◽  
Vol 6 ◽  
pp. S44-S54
Author(s):  
Melodie S. Young ◽  
Nicole Furfaro ◽  
Aarati Rai
Keyword(s):  
Psoriatic Arthritis ◽  
Diagnosis And Management
Sign in / Sign up

Export Citation Format

Share Document